Clinical Trial Update: LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating LDK378 (brigatinib) in ALK-positive non-small cell lung cancer patients previously treated with alectinib has completed and posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• LDK378 (Alectinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Small-Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-12-24